Trials / Completed
CompletedNCT00784732
A Study to Compare the Efficacy of QAV680 Against Placebo in Treating Seasonal Allergic Rhinitis in an Environmental Exposure Chamber
A Randomized, Partially-blinded, Placebo-controlled, Two-way Crossover, Proof of Concept Study to Compare the Relative Efficacy of CRTh2 Receptor Antagonist, QAV680 Against Placebo in the Treatment of Allergic Rhinitis in an Environmental Exposure Chamber (EEC) Model
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 44 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study will compare the effectiveness of QAV680 against placebo in treating the symptoms of seasonal allergic rhinitis in an Environmental Exposure Chamber.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | QAV680 | |
| DRUG | QAV680 | |
| DRUG | Mometasone Furoate |
Timeline
- Start date
- 2008-09-01
- Primary completion
- 2008-12-01
- Completion
- 2008-12-01
- First posted
- 2008-11-04
- Last updated
- 2016-11-18
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT00784732. Inclusion in this directory is not an endorsement.